´ëÇѽɺÎÀüÇÐȸ µ¿°è ½ÉÆ÷Áö¾ö : 2021-12-10
±³À°ÀÏÀÚ : 2021-12-10
±³À°Àå¼Ò : ¾È´ÙÁî ¼¿ï °³² B2Ãþ ºñ¿æµå ´õ ±Û·¡½º & ¾È´ÙÁî ½ºÆ©µð¿À
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ µ¿°è ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ
´ã´çÀÚ : Á¤¼±¿µ
¿¬¶ôó : 02-3275-5335
À̸ÞÀÏ : khfs3@khfs.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 2 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 15:00~15:15 Pulmonary Artery Pressure Monitoring in Ambulatory Patients with Symptomatic Heart Failure Á¤¿íÁø(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 15:15~15:30 Transcatheter Interatrial Shunts for the Treatment of Heart Failure ¹Ú¼º¹Ì(°í·ÁÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 15:30~15:45 Secondary mitral regurgitation strategy ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 15:45~16:00 Ventricular Assist Device as a Bridge to recovery (BTR) ÃÖÁø¿À(¼º±Õ°üÀÇ´ë)
Åä·Ð 12-10 ºñ¿æµå ´õ ±Û·¡½º 16:00~16:20 Discussion ()
ÈÞ½Ä 12-10 ºñ¿æµå ´õ ±Û·¡½º & ¾È´ÙÁî ½ºÆ©µð¿À 16:20~16:40 ()
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 16:40~16:50 ACE inhibitor first rather ARB in HF treatment ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 16:50~17:00 Optimal dose of evidence base B-blocker ¹Ú¼ºÁö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 17:00~17:10 Beneficial phenotype of early SGLT2I use ±è¼ºÇØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 17:10~17:20 Stepwise approach in HFmrEF ¹ÚÀçÇü(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 17:20~17:30 Start ARNI as an initial denovo HF therapy ¹Ú»ó¹Î(À»ÁöÀÇ´ë)
±³À°½Ã°£ 12-10 ºñ¿æµå ´õ ±Û·¡½º 17:30~17:40 4 all-comers or classical stepwise approach in HFrEF Á¶ÇöÀç(¼¿ïÀÇ´ë)
Åä·Ð 12-10 ºñ¿æµå ´õ ±Û·¡½º 17:40~18:00 Discussion ()